Share price
+55.56%
Turnover
0.95 MSEK
Calendar
| Est. time* | ||
| 2026-02-25 | 08:20 | Year-end Report 2025 |
| 2025-11-06 | 08:30 | Quarterly Report 2025-Q3 |
| 2025-08-13 | - | Quarterly Report 2025-Q2 |
| 2025-06-26 | - | Annual General meeting |
| 2025-05-28 | - | Quarterly Report 2025-Q1 |
| 2025-05-21 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2025-02-28 | - | Year-end Report 2024 |
| 2025-01-07 | - | Extra General Meeting 2024 |
| 2024-11-06 | - | Quarterly Report 2024-Q3 |
| 2024-08-15 | - | Quarterly Report 2024-Q2 |
| 2024-05-22 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2024-05-21 | - | Annual General meeting |
| 2024-05-07 | - | Quarterly Report 2024-Q1 |
| 2024-02-23 | - | Year-end Report 2023 |
| 2024-01-11 | - | Extra General Meeting 2023 |
| 2023-10-24 | - | Quarterly Report 2023-Q3 |
| 2023-08-11 | - | Quarterly Report 2023-Q2 |
| 2023-04-24 | - | Quarterly Report 2023-Q1 |
| 2023-04-21 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2023-04-20 | - | Annual General meeting |
| 2023-02-24 | - | Year-end Report 2022 |
| 2023-01-09 | - | Extra General Meeting 2022 |
| 2022-11-10 | - | Quarterly Report 2022-Q3 |
| 2022-08-18 | - | Quarterly Report 2022-Q2 |
| 2022-05-25 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2022-05-24 | - | Annual General meeting |
| 2022-05-12 | - | Quarterly Report 2022-Q1 |
| 2022-02-25 | - | Year-end Report 2021 |
| 2021-12-16 | - | Extra General Meeting 2021 |
| 2021-11-10 | - | Quarterly Report 2021-Q3 |
| 2021-08-18 | - | Quarterly Report 2021-Q2 |
| 2021-06-10 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2021-05-27 | - | Annual General meeting |
| 2021-05-12 | - | Quarterly Report 2021-Q1 |
| 2021-02-26 | - | Year-end Report 2020 |
| 2020-11-10 | - | Quarterly Report 2020-Q3 |
| 2020-08-17 | - | Quarterly Report 2020-Q2 |
| 2020-07-28 | - | Extra General Meeting 2020 |
| 2020-06-30 | - | Annual General meeting |
| 2020-06-17 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2020-05-14 | - | Quarterly Report 2020-Q1 |
| 2020-02-27 | - | Year-end Report 2019 |
| 2019-11-08 | - | Quarterly Report 2019-Q3 |
| 2019-08-16 | - | Quarterly Report 2019-Q2 |
| 2019-06-20 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2019-06-19 | - | Annual General meeting |
| 2019-05-15 | - | Quarterly Report 2019-Q1 |
| 2019-02-27 | - | Year-end Report 2018 |
| 2018-11-09 | - | Quarterly Report 2018-Q3 |
| 2018-08-17 | - | Quarterly Report 2018-Q2 |
| 2018-05-15 | - | Quarterly Report 2018-Q1 |
| 2018-03-29 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2018-03-28 | - | Annual General meeting |
| 2018-02-27 | - | Year-end Report 2017 |
| 2017-11-09 | - | Quarterly Report 2017-Q3 |
| 2017-08-17 | - | Quarterly Report 2017-Q2 |
| 2017-05-19 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2017-05-18 | - | Annual General meeting |
| 2017-05-16 | - | Quarterly Report 2017-Q1 |
| 2017-02-27 | - | Year-end Report 2016 |
| 2016-11-10 | - | Quarterly Report 2016-Q3 |
| 2016-08-17 | - | Quarterly Report 2016-Q2 |
| 2016-07-22 | - | Extra General Meeting 2016 |
| 2016-05-20 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2016-05-19 | - | Annual General meeting |
| 2016-05-17 | - | Quarterly Report 2016-Q1 |
| 2016-02-26 | - | Year-end Report 2015 |
| 2015-11-19 | - | Extra General Meeting 2015 |
| 2015-11-11 | - | Quarterly Report 2015-Q3 |
| 2015-08-17 | - | Quarterly Report 2015-Q2 |
| 2015-05-08 | - | Quarterly Report 2015-Q1 |
| 2015-04-10 | - | Ex-date Ordinary Dividend PMED 0.00 SEK |
| 2015-04-09 | - | Annual General meeting |
| 2015-02-27 | - | Year-end Report 2014 |
| 2014-10-15 | - | Quarterly Report 2014-Q3 |
| 2014-08-13 | - | Quarterly Report 2014-Q2 |
Description
| Country | Sweden |
|---|---|
| List | Spotlight |
| Sector | Health care |
| Industry | Biotechnology |
Peptonic Medical AB (publ.) ("Peptonic" or "the Company") announces that the Uppsala District Court has approved the Company's application for corporate restructuring. This decision enables Peptonic to implement the necessary restructuring to establish a stable and profitable business.
The Uppsala District Court has today approved Peptonic's application for corporate restructuring. The Company's primary focus is now to ensure that business operations remain uninterrupted. Discussions will be initiated with suppliers and business partners to maintain strong and ongoing collaboration.
During the restructuring process, Peptonic, together with the court-appointed administrator, will develop a restructuring plan outlining the necessary measures to overcome the Company's financial challenges and establish a solid foundation for long-term profitability. Peptonic will publish the plan once it is finalized.
Attorney Jonas Premfors from DLA Piper has been appointed by the district court as the administrator and will lead the restructuring process. Within a week, all known creditors will be notified of the decision on the corporate restructuring. A creditors' meeting will be held at the Uppsala District Court on March 26, 2025, at 10:30 AM.
For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish Medical Device company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.